Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and mildly reduced or preserved ejection fraction has not been established. Data regarding the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction are needed. METHODS: In this international, double-blind trial, we randomly assigned patients with heart failure and a left ventricular ejection fraction of 40% or greater, in a 1:1 ratio, to receive finerenone (at a maximum dose of 20 mg or 40 mg once daily) or matching placebo, in addition to usual therapy. The primary outcome was a composite of total worsening heart failure events (with an event defined as a first or recurrent unplanned hospitalization or urgent visit for heart failure) and death from cardiovascular causes. The components of the primary outcome and safety were also assessed. RESULTS: Over a median follow-up of 32 months, 1083 primary-outcome events occurred in 624 of 3003 patients in the finerenone group, and 1283 primary-outcome events occurred in 719 of 2998 patients in the placebo group (rate ratio, 0.84; 95% confidence interval [CI], 0.74 to 0.95; P = 0.007). The total number of worsening heart failure events was 842 in the finerenone group and 1024 in the placebo group (rate ratio, 0.82; 95% CI, 0.71 to 0.94; P = 0.006). The percentage of patients who died from cardiovascular causes was 8.1% and 8.7%, respectively (hazard ratio, 0.93; 95% CI, 0.78 to 1.11). Finerenone was associated with an increased risk of hyperkalemia and a reduced risk of hypokalemia. CONCLUSIONS: In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo. (Funded by Bayer; FINEARTS-HF ClinicalTrials.gov number, NCT04435626.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Of the enrolled participants, 41% had type 2 diabetes.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [303]
The cited source says what the claim attributes to it.
In the citing paper
“The selective nonsteroidal MRA finerenone was examined in the Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF) trial of people with symptomatic HFpEF (ejection fraction ≥40%) and was found to reduce the risk of”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [303]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationPitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Self-citationEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationEplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationAngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Self-citationCardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 401–500 of 892
Diagnosis and management of diastolic dysfunction in arterial hypertension
Blanch, P., & Freixa‐Pamias, R. (2025) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2025.06.002 · Cited by 3
López-Guillén, J. L., Esmel-Vilomara, R., Rodoman, I., Constante, A. D., Kendall, I. S., Freixa‐Benavente, A., Diaz‐Gil, D., Cantarutti, N., Moscatelli, S., & Jeewa, A. (2025) · European Journal of Pediatrics · doi:10.1007/s00431-025-06263-w · Cited by 2
Polypill in heart failure: a pathway to simplified treatment and improved adherence and outcomes
Keramida, K., Savarese, G., Filippatos, G. S., & Yusuf, S. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10559-2 · Cited by 2
Self-citationDeng, L., Tighiouart, H., Oka, T., Tuttle, M. L., Downey, B. C., Rowin, E. J., Ho, J. E., Sarnak, M. J., & McCallum, W. I. (2026) · Kidney360 · doi:10.34067/kid.0000001186 · Cited by 2
The FINE ART of Interpreting Health Status Benefits in Clinical Trials
Spertus, J. A., Cohen, D. J., & Arnold, S. V. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.10.095 · Cited by 2
Increasing Readmissions of HFpEF and the Burden They Cause
Kim, M., & Lee, C. J. (2025) · International Journal of Heart Failure · doi:10.36628/ijhf.2025.0001 · Cited by 2
Toward a New SUMMIT in Heart Failure with Preserved Ejection Fraction
Felker, G. M. (2025) · New England Journal of Medicine · doi:10.1056/nejme2415551 · Cited by 2
Yoon, M., Park, J. J., & Greenberg, B. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag025 · Cited by 2
The role of finerenone in the management of CKD in T2D –Practical considerations for primary care
Kanumilli, N., Miszon, M., Schnell, O., & Groop, P. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.09.001 · Cited by 3
Heart Failure in Brazil: How Can We Improve its Natural History?
Ferrari, F., Rossi, A. P., & Santander, I. R. M. F. (2024) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240644i · Cited by 1
Conde, A. C., Martínez, J. J. G., & Lorite, N. M. (2024) · REC CardioClinics · doi:10.1016/j.rccl.2024.11.004 · Cited by 1
Advances in Cardiorenal Medicine: The Year 2024 in Review
Kazory, A., & Ronco, C. (2025) · Cardiorenal Medicine · doi:10.1159/000544817 · Cited by 1
“In 2024, the results of the Finerenone Trial to In-vestigate Ef fi cacy and Safety Superior to Placebo in Patients with Heart Failure (FINEARTS-HF) were released [8].”
Ren, Y., Schloemer, P., & Wang, M. (2025) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2025.2468466 · Cited by 1
Miró, Ò., Peyrony, O., Trullàs, J. C., Alquézar‐Arbé, A., Núñez, J. E., López‐Ayala, P., Jacob, J., Bueno, H., Montero-Pérez-Barquero, M., Arévalo‐Lorido, J. C., et al. (2025) · Revista Española de Cardiología · doi:10.1016/j.recesp.2025.02.019 · Cited by 1
Miró, Ò., Peyrony, O., Trullàs, J. C., Alquézar‐Arbé, A., Núñez, J. E., López‐Ayala, P., Jacob, J., Bueno, H., Montero-Pérez-Barquero, M., Arévalo‐Lorido, J. C., et al. (2025) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2025.02.021 · Cited by 4
Effects of Finerenone on Readmissions for Heart Failure: Insights From the FINEARTS-HF Trial
Bhatt, A. S., Vaduganathan, M., Claggett, B. L., Jhund, P. S., Henderson, A. D., Lam, C. S. P., Senni, M., Shah, S. J., Desai, A. S., Voors, A. A., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.05.006 · Cited by 1
Self-citationIn-Hospital Management of Acute Heart Failure
Kittleson, M. M., Raj, L. M., & Smith, D. T. (2025) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.03.001 · Cited by 2
Mortality and Economic Impact of Heart Failure
Gillet, A. S., & Stewart, G. C. (2025) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.04.012 · Cited by 1
Wolf, P. J. W., Correia, E. B., Neto, J. M. R., Finger, M. A., dos Santos, C. C., de Vasconcellos, M. A. B., Bruscky, L. V. R., Murta, A. C. D. S., Francisco, Y. A., Albrecht, F. C., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240676i · Cited by 1
“37 Finerenone is, therefore, the second treatment that has demonstrated a significant impact on HFpEF/HFpEF, reinforcing the management of this clinical condition with high morbidity and mortality.”
Finerenone in Heart Failure—Reply
Vaduganathan, M., McMurray, J. J. V., & Solomon, S. D. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.1533 · Cited by 1
Self-citationManagement of atrial fibrillation in patients with heart failure with preserved ejection fraction
Rambarat, P. K., DeVore, A. D., Mark, D. B., Bahnson, T. D., & Piccini, J. P. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10536-9 · Cited by 1
Attachaipanich, T., Kaewboot, K., & Attachaipanich, S. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2530842 · Cited by 1
Shang, C., Ma, J., Liang, H., Zhang, Y., & Sui, Y. (2025) · Endocrine Research · doi:10.1080/07435800.2025.2533762 · Cited by 1
Marques, I., Severo, M., Pinto, A., Fonseca, C., & Carvalho, H. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14145079 · Cited by 1
“In fact, recently, finerenone improved QoL, but not NYHA class, in patients with LVEF ≥ 40% [27].”
Self-citationOkumura, T., Kusunose, K., Tsuji, T., Kotoku, J., Todaka, K., & Saku, K. (2025) · Cardiology Discovery · doi:10.1097/cd9.0000000000000168 · Cited by 1
Font, J., Hodžić, A., Silva, A. D., Delapierre, B., Damaj, G. L., Neusy, A. J., Plane, A., Legallois, D., Milliez, P., Dolladille, C., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13092184 · Cited by 1
“More recently, MRAs such as finerenone have also shown beneficial effects on HF outcomes in patients with mildly reduced or preserved ejection fraction [22,23,37,38].”
Evaluation of pulmonary hypertension in heart failure with preserved ejection fraction
Cao, J. J. L., & Reddy, Y. N. V. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10553-8 · Cited by 1
Kashiwagi, M., Kuroi, A., Higashimoto, N., Hata, S., Taruya, A., Shiono, Y., Yamano, T., Tanimoto, T., Kitabata, H., & Tanaka, A. (2025) · Cureus · doi:10.7759/cureus.91898 · Cited by 1
CHENG, A. Y. Y., Mottl, A. K., & MAGWIRE, M. L. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01796-7 · Cited by 5
“…participant-level pooled analysis ( N = 18,991) of the FIDELIO-DKD (NCT02540993) [35], FIGARO-DKD (NCT02545049) [36], and FINEARTS-HF (NCT04435626)[37] trials in participants with heart failure and CKD with T2D, finerenone significantly reduced all-cause mortality (HR, 0.91; 95% CI 0.84–0.99; P =…”
InfluentialPulmonale Hypertonie bei Linksherzerkrankungen
Schmidt, K. H., Adler, J., Bikou, O., Felgendreher, R., Hohenforst‐Schmidt, W., Holt, S., Kleber, F. X., Ladage, D., Lichtblau, M., Pfeuffer-Jovic, E., et al. (2025) · Pneumologie · doi:10.1055/a-2625-4920 · Cited by 1
“Welche Wirkung die Therapie mit dem nicht-steroidalen Mineralokortikoid-Rezeptor-Antagonisten Finerenon auf die PH-LHD hat, ist bislang noch unklar [25].”
Parsing the Adipokine Axis in HFpEF
Verma, S., & Bhatt, D. L. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.035 · Cited by 2
Self-citationHanatani, S., Nakashima, N., Ogata, F., Yamamoto, M., Okuno, Y., Yamada, T., Yamamura, S., Araki, S., Arima, Y., Yamamoto, E., et al. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152802 · Cited by 1
Advancing Heart Failure Care: Breakthroughs and Emerging Strategies
Tedeschi, A., Barocelli, F., Gerra, L., Breviario, F., Palazzini, M., Conti, N., Ferraro, S., Bolognesi, M. G., Spigno, F. D., Gentile, P., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14207253 · Cited by 5
“[39].”
Luca, C. D., Bhatt, H., Gupta, A., Yahyavi, A., Banivaheb, B., Rayner, D. G., Anderson, K., Zieroth, S. R., Virani, S., Foroutan, F., et al. (2025) · CJC Open · doi:10.1016/j.cjco.2025.05.021 · Cited by 2
“7 Lastly, the patient population included in the FINEARTS-HF trial was better de fi ned than that in TOPCAT, a trial that was marred by regional concerns about the diagnosis of HF and study drug compliance in the treatment arm.”
InfluentialSelf-citationPoulsen, M. B., Okdahl, T., Buciek, J. H., Drewes, A. M., Karlsson, P., Ahluwalia, T. S., Brock, B., Brock, C., Rossing, P. R., & Hansen, C. S. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-101074 · Cited by 2
“19 Trials in diabetic kidney disease using steroidal MRAs have been precluded by hyperkalaemia.”
Regulation of Klotho Production by Mineralocorticoid Receptor Signaling in Renal Cell Lines
Kohm, E., Feger, M., & Föller, M. (2025) · Biomolecules · doi:10.3390/biom15111509 · Cited by 1
Chronic kidney disease for the primary care provider
Doak, W., Lerma, E. V., & Shah, A. D. (2025) · Disease-a-Month · doi:10.1016/j.disamonth.2025.102027 · Cited by 2
Hida, Y., Imamura, T., & Kinugawa, K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14227997 · Cited by 2
“More recently, the FINEARTS-HF trial demonstrated that finerenone reduces the risk of HF events in patients with HF with preserved or mildly reduced ejection fraction (HF-pEF/HFmrEF) [14].”
InfluentialNuclear receptors as therapeutic targets in metabolic and cardiovascular disorders
Li, F., Chen, Q., Dai, Y., & Lu, L. (2025) · iScience · doi:10.1016/j.isci.2025.114042 · Cited by 1
What to do with key cardiovascular drugs when kidney function worsens?
Bergen, K., & Spaak, J. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf354 · Cited by 1
“Kidney outcomes ( 50% reduction in eGFR or kidney failure) were few but numerically higher in the Finerenone group, although not significant [89 ].”
Management of HFpEF in Asian Patients
Hung, C., Chiang, C., & Yeh, H.-I. (2025) · JACC Asia · doi:10.1016/j.jacasi.2025.09.014 · Cited by 1
Self-citationThe changing landscape of heart failure: translating management into the modern era
Madaudo, C., Ibrahim, W., Noakes, D., Bromage, D. I., Sinagra, G., McDonagh, T., & Cannata, A. N. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106633 · Cited by 1
Clinical Features and Outcomes of Patients with Heart Failure and Advanced Chronic Kidney Disease
Gámez, M. A., Flores, J. H., Bonilla‐Palomas, J. L., Mayoral, A. R., Manzanares, R. G., Castillo, J. C., Aguilera, J. L., Muñiz, J., & Anguita-Sánchez, M. P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238508 · Cited by 2
“…specifically analyzed the impact of advanced CKD, with GFR 30 mL/min/m 2 , on the prognosis of HF, as well as on its pharmacological treatment, because HF registries do not distinguish the degree of renal function impairment [3,19–22], and clinical trials exclude these patients [14–17 ,23, 24 ].”
Foà, A., Vaduganathan, M., Claggett, B. L., Desai, A. S., Jhund, P. S., Henderson, A. D., Chatur, S., Amarante, F., Hofmeister, L. H., Horvat-Broecker, A., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102779 · Cited by 1
Self-citationPagnesi, M., Riccardi, M., Maisano, F., Antohi, E., Barberis, V. I., Hamid, M. A., Arfsten, H., Grapsa, J., Karam, N., Muraru, D., et al. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvaf027 · Cited by 1
Kereiakes, D. J., Tedford, R. J., Lindenfeld, J. M., Gray, W. A., Zahr, F. E., Lurz, P. C., Hibbert, B. M., Baron, S. J., Cavalcante, J. L., Jorde, U. P., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuaf016 · Cited by 1
Proteomic patterns according to ejection fraction: an EMPEROR-programme analysis
Ferreira, J. P., Fioretti, F., Sumin, M., Anker, S. D., Filippatos, G. S., Kuhn, M. M., Panova‐Noeva, M., Prochaska, J. H., Saadati, M., Stolze, B., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag013 · Cited by 2
Self-citationChimura, M., Jhund, P. S., Henderson, A. D., Claggett, B. L., Desai, A. S., Lay‐Flurrie, J., Scalise, A. V., Rohwedder, K., Lam, C. S. P., Senni, M., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag008 · Cited by 1
Self-citationRodríguez, J. M. F., Ortiz, M. B. A., Cerrada, J. C., Chivite, D., Romano, P. C., Alonso, R. G., Almorós, A. L., Miramontes‐González, J. P., Rangel, L. S., & Pérez-Silvestre, J. (2026) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2026.502471 · Cited by 1
Verelst, F. R., Witte, K. K., Ahmed, F. Z., Al‐Khatib, S. M., Parkash, R., Gevaert, A. B., & Spall, H. G. C. V. (2026) · Heart · doi:10.1136/heartjnl-2025-326954 · Cited by 1
Reddy, Y. N. V., Bergeron, N. P., Carter, R. E., Redfield, M. M., & Borlaug, B. A. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.047295 · Cited by 2
Mineralocorticoid Receptor Antagonists: The Pillar Drug in Heart Failure
Sethi, R., Jain, R., Raj, R. A., Jaya, P. V., Arora, M., Thakran, V., Pandey, R. K., Sharma, J., Rao, K. M. M., Sharma, H., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1296 · Cited by 3
Ghimire, A., Al-Zaneen, G., Michaud, J. B., Worthen, G. L., Rampersad, C., Singh, S. K. S., Lam, N. N., Kim, S. J., Tennankore, K., & Vinson, A. J. (2026) · Cardiology and Therapy · doi:10.1007/s40119-026-00446-8 · Cited by 2
“The recent FINEARTS trail showed that finerenone was associated with a reduction in recurrent unplanned hos‑ pitalization or urgent visits for HF (rate ratio, 0.82; 95% CI 0.71–0.94; P = 0.006) among par‑ ticipants with LVEF > 40% [109].”
InfluentialMartyn, T., Helou, M. C. E., Zalaquett, Z., Rajendran, J., Patolia, H. H., Albert, N. M., Bhatt, A. S., Butler, J., Block‐Beach, H., Kapadia, S. R., et al. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.02.016 · Cited by 1
Mineralocorticoid receptor antagonists: Efficacy and safety in chronic kidney disease
Mottl, A. K., Khunti, K., & Mathieu, C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70587 · Cited by 2
“54 The reported incidence of sex-related AEs was similar with eplerenone and placebo because eplerenone exhibits a higher selectivity for the MR, unlike spironolactone.”
Nishino, M., Egami, Y., Mukai, T., Kise, M., Sugino, A., Kobayashi, N., Abe, M., Nohara, H., Kawanami, S., Yasumoto, K., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag071 · Cited by 2
Comorbidity-Driven Inflammation in HFpEF: Immune Profiling and Therapeutic Targets
Cami, E., Verghote, E., Pecetto, E., González, A., Bråkenhielm, E., Jones, E. A. V., & van Empel, V. P. M. (2026) · Current Heart Failure Reports · doi:10.1007/s11897-026-00745-0 · Cited by 2
“Evidence for finerenone in HFpEF is directly supported by the FINEARTS trial, demonstrating a 16% reduction in the primary endpoint of worsening HF events [126 ].”
Hamatani, Y., Claggett, B. L., Desai, A. S., Lewis, E. F., Jhund, P. S., Lam, C. S. P., Martínez, F. A., Zannad, F. M., Pfeffer, M. A., McMurray, J. J. V., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.03.026 · Cited by 2
Self-citationJiang, Y., Hu, J., Yi, X., Li, Q., & Yang, S. (2026) · Drugs · doi:10.1007/s40265-026-02302-4 · Cited by 2
Monzo, L., Huttin, O., Bresso, E., Duarte, K., Linde, C. M., Lund, L. H., Hage, C., Donal, E., Magnusson, M., Nilsson, P. M., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag039 · Cited by 1
Self-citationHeart Failure Therapies and Renal Effects: A Critical Reevaluation of Clinical Data
Gronda, E., Iacoviello, M., Palazzuoli, A., Carugo, S., Arduini, A., Gabrielli, D., & Tavazzi, L. (2026) · Journal of CardioRenal Medicine · doi:10.3390/jcrm2010005 · Cited by 1
“[53].”
A Review on Finerenone and Heart Failure with Preserved Ejection Fraction (HFpEF)
Senapati, S. G., & Mukherjee, D. (2026) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x457971260121071610 · Cited by 1
Geagea, M., Kozaily, E., Buchanan, C. J., Litwin, S. E., & Tedford, R. J. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10601-x · Cited by 1
Mancini, B. W., & Mysore, M. M. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.03.029 · Cited by 1
The diagnosis and subclassification of heart failure with preserved ejection fraction: a review
Creegan, D., Starling, R. C., Hameed, A. G., Daly, M. J., & O’Neill, J. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10618-2 · Cited by 2
Wyss, F. S., Ullauri, V. E., Lara-Terán, J. J., Arteaga-Arellano, A., Martín, C. G., López-Santi, R., Pérez, G., Madrigal, C. A., Ger, M., Piskorz, D. L., et al. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02157-5 · Cited by 3
“Finerenone reduces the risk of worsening heart failure events and cardiovascular death in patients with heart failure and FEY ≥ 40% (Table 20) [191].”
Persson, H., Winderud, A., Hage, C., Cabrera, C. C., Löfström, U., Lyngå, P., Arslan, T., Knudsen-Malmqvist, K., Eriksson, M. J., Persson, B., et al. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag105 · Cited by 1
“This aligns with the FINEARTS-HF trial, which reported 88% hypertension in HFpEF/HFmrEF, 12 underscoring the central role of hypertension in HFpEF.”
Endocrinology: What You May Have Missed in 2025
Escudero, C., Havranek, K., Cruz, M. M., & Batch, B. C. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-00925 · Cited by 1
Reversible Fibroblast Trajectories Regulated by MR Underlie Diastolic Dysfunction
Meral, D., Mamazhakypov, A., Koca, D., Mukherjee, D., Kamaras, C., Emig, R., Peyronnet, R., Preißl, S., & Lother, A. (2026) · Circulation Research · doi:10.1161/circresaha.125.327301 · Cited by 2
Sánchez‐Bayuela, T., Soulié, M., Garaikoetxea, M., Fernández‐Celis, A., López‐Andrés, N., & Jaisser, F. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.047941 · Cited by 1
“24 conducted in patients with CKD and type 2 diabetes 22,23 and in patients with heart failure and mildly reduced or preserved ejection fraction, 24 respectively, provide indirect but compelling support for the potential clinical translation of our findings.”
The Role of β-Blockers in the Evolving Treatment Landscape of Resistant Hypertension
Masi, S., Pathak, A., Bruno, R. M., Brouwers, S., Narkiewicz, K., Taddei, S., Tsioufis, K. P., & Kreutz, R. H. (2026) · Drugs · doi:10.1007/s40265-026-02319-9 · Cited by 4
“Similarly, in patients with heart failure with pre-served or mildly reduced ejection fraction, MRAs have demonstrated outcome benefits [140], whereas β-blockers lack an equally compelling evidence-based indication in this setting.”
Wilcox, J. E., Lund, L. H., Cox, Z. L., Ho, J. E., Lam, C. S. P., Sharma, K., & Borlaug, B. A. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.01.024 · Cited by 3
Self-citationWen, S., Wang, C., Xu, Z., Chen, L., He, Y., Ren, Y., Yuan, Y., Li, Y., Dong, M., Gong, M., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03164-6 · Cited by 1
“Subgroups with LVEF ≥ 40% and renal comorbidities showed consistent gains, underscoring its versatility [73].”
Kuo, Y.-J., Chen, L.-F., Chen, Y., Chen, P., & Lin, H. Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094120 · Cited by 4
Kwa, S. L., Chung, B. K., Tan, Z. F., Wong, J. K. W., Lian, Z. Y., Cheah, K. C., Tan, K.-S., Lam, C.-H., Khaw, M. J., Chai, S. Y., et al. (2026) · BMC Geriatrics · doi:10.1186/s12877-026-07571-y · Cited by 1
“Recent trials of non-steroidal MRA have shown improved heart failure outcomes with favourable tolerability profiles, including among older adults [40, 41].”
Self-citationFu, Z., Chen, X., Liu, H., Yang, J., Jin, T., Liu, T., & Ta, G. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1813205 · Cited by 2
“…in the finerenone group compared with 55 in the placebo group (HR = 1.33, 95% CI 0.94–1.89), with no statistically significant difference observed between groups, suggesting that no clear reduction in the risk of composite renal outcomes was evident in this population (Solomon et al., 2024).”
InfluentialHeinzl, M. W., Resl, M., Maier, J., Steinwender, C., Falkensammer, J., Fellinger, P., Steinmaurer, T., Saely, C. H., Hoppichler, F., Stingl, H., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02667-8 · Cited by 1
A simplified, tier-based method for clinical evaluation of diastolic function
Argulian, E., Nagueh, S. F., Grapsa, J., & Smiseth, O. A. (2026) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeag123 · Cited by 1
Boettger, P., Sedighi, J., Sohns, C., Bauersachs, J. K., Aßmus, B., & Sossalla, S. T. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag167 · Cited by 1
Self-citationWang, T., Wang, T., & Zhang, R. (2026) · Annals of Pharmacotherapy · doi:10.1177/10600280261447498 · Cited by 1
Saey, S. A., Adel, F., & Chen, H. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2026.03.025 · Cited by 1
Oishi, H., Kondo, T., Ito, R., Kazama, S., Haga, T., Murase, Y., Yamaguchi, S., Furui, K., Kaneko, S., Imai, H., et al. (2026) · Heart and Vessels · doi:10.1007/s00380-026-02716-w · Cited by 1
Effects of Finerenone on Sudden Death Across the Cardio-Kidney-Metabolic Landscape
Foà, A., Pabón, M. A., Filippatos, G. S., Claggett, B. L., Miao, Z. M., Jhund, P. S., Henderson, A. D., BRINKER, M. D., Lage, A. Z., Hofmeister, L. H., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.04.045 · Cited by 2
Self-citationLo, K. B., Ostrominski, J. W., Hamatani, Y., Claggett, B. L., Agarwal, R., Anker, S. D., Filippatos, G. S., Rossing, P. R., Ruilope, L. M., Pitt, B., et al. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.1365 · Cited by 2
Self-citationZhu, W., Peng, J., Yan, Z., Chen, Y., Xu, J., & Zhang, L. (2026) · Frontiers in Digital Health · doi:10.3389/fdgth.2026.1730457 · Cited by 2
Carlino, I., Franco, S. D., Colalillo, N., Bisogno, S., Gennari, L., & Palazzuoli, A. (2026) · Biomedicines · doi:10.3390/biomedicines14061289 · Cited by 1
“Novel therapies should therefore be considered complementary rather than replacement strategies [64].”
Spironolactone and New-Onset Diabetes in Heart Failure
Nguyen, D. V., & Nguyen, H. T. T. (2026) · JACC Asia · doi:10.1016/j.jacasi.2026.04.010 · Cited by 1
Packer, M., Butler, J., Ho, J. E., Lam, C. S. P., Petrie, M. C., Schiattarella, G. G., Vaduganathan, M., Zannad, F. M., & Borlaug, B. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.05.016 · Cited by 1
Self-citationYang, D. X., Thakur, S., Akunor, H., Stacey, R. B., & Upadhya, B. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13070291 · Cited by 2
“In the FINerenone trial to investigate Efficacy and sAfety superioR to placebo in paTientS with Heart Failure (FINEARTS-HF) trial (n = 6001; LVEF ≥ 40%), it reduced the risk of worsening HF events and CV death by 16% [118].”
Agarwal, R., Pandey, A., Solomon, S. D., Vaduganathan, M., & Zannad, F. M. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag150 · Cited by 4
Self-citationSperry, B. W., Carlino, I., & Palazzuoli, A. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10652-0 · Cited by 1
Bozduman, F., Ceren, İ., & Şener, Y. Z. (2026) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2026.2664091 · Cited by 1
“While the benefits of GRMT are most firmly established in HFrEF, emerging evidence supports the efficacy of SGLT2 inhibitors and finerenone in patients with HFmrEF and HFpEF [29].”
Lund, L. H., & Pitt, B. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag450 · Cited by 1
Self-citationHeart Failure Pharmacotherapy Across the Transcatheter Aortic Valve Replacement Continuum
Onishi, T., Tang, G. H. L., Moyal, A., Santosh, K., Swaminathan, S., Johanna, C., Moss, N., Khera, S., Hooda, A., Dangas, G., et al. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.06.011 · Cited by 1
Finerenone and Blood Pressure in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Ostrominski, J. W., Claggett, B. L., Kulac, I. J., Desai, A. S., Jhund, P. S., Henderson, A. D., Lam, C. S. P., Senni, M., Shah, S. J., Voors, A. A., et al. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.2104 · Cited by 1
Self-citationGolec, S., Vaidya, A., Pitt, B., & Jaffe, I. Z. (2026) · Circulation Research · doi:10.1161/circresaha.126.327593 · Cited by 2
Self-citationPacker, M., Schiattarella, G. G., Petrie, M. C., Burkhoff, D., Butler, J., Lam, C. S. P., Zannad, F. M., Vaduganathan, M., & Borlaug, B. A. (2026) · Circulation · doi:10.1161/circulationaha.126.079235 · Cited by 3
Self-citationDons, M., Sengeløv, M., Borchsenius, J., Ottosen, C. I., Fudim, M., Weber, B., Spall, H. G. C. V., & Biering‐Sørensen, T. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.045770 · Cited by 2
“109 In 2025, based on the FINEARTS-HF results, the Food and Drug Administration approved finerenone for adults with HF with mildly reduced EF and HFpEF.”
Pecoits-Filho, R., Banerjee, D., Jardine, M., Neuen, B. L., Soler, M. J., Ahmed, S. B., Anderson, L. J., Bavanandan, S., Bansal, S., Burton, J. O., et al. (2026) · Kidney International · doi:10.1016/j.kint.2026.06.044 · Cited by 2
Self-citationCardiovascular–Kidney–Metabolic Syndrome: Models of Care
Chung, I., Fricska, D. I., Banerjee, S., Banerjee, P., Gomez-Johnson, V. H., Annear, N. M. P., Chaudhury, A. R., Chen, M., Anderson, L., & Banerjee, D. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm47862 · Cited by 1
“…randomized controlled trials have identified therapies that confer benefits across all three systems, such as sodium–glucose co-transporter 2 (SGLT-2) inhibitors [13], glucagon-like peptide-1 (GLP-1) agonists [14], and non-steroidal mineralocorticoid receptor inhibitors [15].”
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Vaduganathan, M., Claggett, B., Jhund, P. S., Desai, A. S., Henderson, A. D., Lam, C. S. P., Pitt, B., Senni, M., Shah, S. J., Voors, A. A., Zannad, F., Abidin, I. Z., Alcocer-Gamba, M. A., Atherton, J. J., Bauersachs, J., Chang-Sheng, M., Chiang, C.-E., Chioncel, O., Chopra, V., Comin-Colet, J., Filippatos, G., Fonseca, C., Gajos, G., Goland, S., Goncalvesova, E., Kang, S., Katova, T., Kosiborod, M. N., Latkovskis, G., Lee, A. P.-W., Linssen, G. C. M., Llamas-Esperón, G., Mareev, V., Martinez, F. A., Melenovský, V., Merkely, B., Nodari, S., Petrie, M. C., Saldarriaga, C. I., Saraiva, J. F. K., Sato, N., Schou, M., Sharma, K., Troughton, R., Udell, J. A., Ukkonen, H., Vardeny, O., Verma, S., von Lewinski, D., Voronkov, L., Yilmaz, M. B., Zieroth, S., Lay-Flurrie, J., van Gameren, I., Amarante, F., Kolkhof, P., & Viswanathan, P.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School, Boston (S.D.S., M.V., B.C., A.S.D.); British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (J.J.V.M., P.S.J., A.D.H., M.C.P.), and Bayer, Reading (J.L.-F.) — both in the United Kingdom; National Heart Centre Singapore and Duke–National University of Singapore, Singapore (C.S.P.L.); University of Michigan School of Medicine, Ann Arbor (B.P.); University of Milano-Bicocca and Papa Giovanni XXIII Hospital, Bergamo (M. Senni), and the Department of Cardiology, University of Brescia, and ASST “Spedali Civili” Hospital, Brescia (S.N.) — all in Italy; Northwestern University Feinberg School of Medicine, Chicago (S.J.S.); University Medical Center Groningen, Groningen (A.A.V.), the Department of Cardiology, Hospital Group Twente, Almelo (G.C.M.L.), and Bayer, Hoofddorp (I.G.) — all in the Netherlands; Université de Lorraine, INSERM Clinical Inv...
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Vaduganathan, Muthiah
- Claggett, Brian
- Jhund, Pardeep S.
- Desai, Akshay S.
- Henderson, Alasdair D.
- Lam, Carolyn S.P.
- Pitt, Bertram
- Senni, Michele
- Shah, Sanjiv J.
- Voors, Adriaan A.
- Zannad, Faiez
- Abidin, Imran Zainal
- Alcocer-Gamba, Marco Antonio
- Atherton, John J.
- Bauersachs, Johann
- Chiang, Chern-En
- Chioncel, Ovidiu
- Chopra, Vijay
- Filippatos, Gerasimos
- Fonseca, Cândida
- Gajos, Grzegorz
- Goland, Sorel
- Kosiborod, Mikhail N.
- Latkovskis, Gustavs
- Lee, Alex Pui-Wai
- Linssen, Gerard C.M.
- Melenovský, Vojtěch
- Merkely, Béla
- Nodari, Savina
- Petrie, Mark C.
- Saldarriaga, Clara Inés
- Saraiva, Jose Francisco Kerr
- Sato, Naoki
- Schou, Morten
- Troughton, Richard
- Udell, Jacob A.
- Ukkonen, Heikki
- Vardeny, Orly
- Verma, Subodh
- von Lewinski, Dirk
- Voronkov, Leonid
- Zieroth, Shelley
- Kolkhof, Peter
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-24
- Volume
- 391
- Issue
- 16
- Pages
- 1475-1485
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4402101139
- Cited by
- 893
- References
- 21
- Citations by year
- 2026: 414 · 2025: 398 · 2024: 81
- FWCI
- 268.66
- Type
- journal article
- Language
- en
- Open access
- green
- hal.univ-lorraine.fr
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Bayer
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- finerenone, heart failure with mildly reduced ejection fraction, heart failure with preserved ejection fraction, mineralocorticoid receptor antagonists, non-steroidal mineralocorticoid receptor antagonists, cardiovascular mortality, hyperkalemia, hypokalemia, FINEARTS-HF trial, left ventricular ejection fraction, heart failure hospitalization, drug safety
- MeSH terms
- Aged, Aged, 80 and over, Mineralocorticoid Receptor Antagonists, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Naphthyridines, Stroke Volume, Treatment Outcome, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.